Beijing Strong Biotechnologies, Inc. successively reached strategic cooperation with Jilin Sinopharm and Liaoning Sinopharm

On April 21, 2021, Beijing Strong Biotechnologies, Inc.(BSBE) and Sinopharm Jilin Medical Technology Co., Ltd. signed a strategic cooperation agreement on the sales of BSBE in Siping City, Jilin Province. The agreement clarified the principles and objectives of cooperation, and determined the sales method and Supply price, etc.

On April 22, 2021, BSBE signed a strategic cooperation agreement with Liaoning Free Trade Sinopharm Device.

In the two signing ceremonies, BSBE deepened its cooperation with local hospitals and at the same time expanded its customer base by relying on the channels of Sinopharm. In the future, BSBE will replicate this model in the rest of the country. The cooperation will not only promotes the business development of the company across the country, and brings significant increase in sales to the company, but also deepens the cooperation between Sinopharm and BSBE in the field of in vitro diagnostics, fully stimulates the vitality of in vitro diagnostics market players, optimizes resource allocation, and achieves mutual win-win effect.

BEAVER completed the B round financing of tens of millions yuan

Recently, BEAVER Biomedical Engineering Co.,Ltd.announced the completion of a round B financing of tens of millions of yuan.

After completing the B round of financing, BEAVER will further increase the mass production of the third-generation chemiluminescence and immuno-capture magnetic beads, and at the same time promote the in-depth development of the fourth-generation nano magnetic beads advanced manufacturing technology, position the global market, and build an industrialization base for biomedical-related products based on the core technology of nano magnetic beads, and comprehensively improve the ability of clinical and non-clinical biological sample processing full-process automation solutions.

Demeter completed the A round of financing of tens of millions yuan 

On April 19th, Hunan Demeter instrument Co., Ltd.  (“Demeter”), which specializes in the clinical research of mass spectrometry, announced the completion of tens of millions of yuan in round A financing.

Demeter breaks through the core technical barriers of clinicalization in the field of mass spectrometry through independent innovation, and changes the clinical application characteristics of chromatography and mass spectrometry. After 12 years of research and development, the company has mastered the control technology of chromatography and mass spectrometry, and has successfully developed a fully automatic two-dimensional liquid chromatography system and a highly stable clinical mass spectrometry system to achieve the detection of most blood drug concentrations, vitamins, amino acids, bile acids, etc. It has substantial competitiveness in patent layout, product manufacturing, technology research, compliance layout and market performance. At present, the company's products have covered 32 provinces and cities across the country, entered hundreds of tertiary hospitals, and accumulated sales of over 100 million yuan.